May 2014

May 2014

REGISTER TODAY

for Rejuvenation Biotechnology 2014

 

Where:  Hyatt Regency Santa Clara, Santa Clara, CA

When:  August 21 – 23, 2014
To Register:  http://sens.org/rb2014
 

SENS Research Foundation invites everyone in our community to register and participate in RB2014, our first major conference set in the heart of Silicon Valley. Discounted Early Bird ticket rates apply until June 30, 2014, so if you are planning on attending, you can save by registering as soon as possible. Also be sure to book your hotel room at the Hyatt Regency Santa Clara using this link to receive our special conference rate.

 

Our conference theme -- Emerging Regenerative Medicine Solutions for the Diseases of Aging -- reflects our ongoing determination to not only develop these solutions in the laboratory, but to build the collaborations essential to the success of rejuvenation biotech becoming a new medical standard for age-related disease. In other words, RB2014 will absolutely feature scientific content meeting the same high standard as our prior Cambridge conferences, but we are broadening the scope of our approach to better reflect the reality of what it will take to end the suffering of age-related disease for everyone, for good. This means bringing together not just researchers, but medical, industrial, social, and fiscal leaders and innovators. 

 

As such, we are delighted to announce the following NEW confirmed speakers:

  • Julie Allickson, Wake Forest Institute for Regenerative Medicine
  • Ashley Ian Bush, University of Melbourne, Massachusetts General Hospital, Harvard Medical School.
  • Guillermo Garcia Cardena, Harvard Medical School, Brigham and Women's Hospital
  • Christy Carter, Institute on Aging, University of Florida
  • Gabor Forgacs, University of Missouri-Columbia, Organovo
  • Dana Goldman, University of Southern California 
  • Neil Littman, ‎California Institute for Regenerative Medicine
  • Peter Nakada, Risk Management Solutions, Inc
  • Bernard Siegel, Genetics Policy Institute
  • Einar M. Sigurdsson, New York University
  • Claude Wischik, University of Aberdeen (Scotland), TauRX Therapeutics, LTD.

Click to view the full list of confirmed speakers on our website.

 

Sponsorships are also available; click to learn more, or contact Jerri Barrett, VP of Outreach, jerri.barrett@sens.org.

 
Seating is limited so register today!

 

RB2014 Conference: Call For Poster Abstracts

 

 

 

 

Students and researchers are invited to submit poster abstracts for the Rejuvenation Biotechnology Conference Poster Session. Poster submissions will be evaluated by members of the SENS Research Foundation Team.

 

Note that students submitting accepted posters will be given a 50% discount on the conference fee.

 

Conference topics include research studying the diseases of aging and the business, economic, finance and regulatory issues that are impacting the future of healthcare such as:
  • Alzheimer’s Disease
  • Cancer
  • Cardiovascular Disease
  • Stem Cell Research
  • Drug development
  • Economics of Healthcare
  • Risk-Benefit Analysis in Aging
  • New Investment and Research 
  • Paradigms in Regenerative Medicine

Click to download the Call For Posters flyer (we encourage you to print, post, and share!). The deadline for poster abstract submissions is June 30, 2014.

 

Submit your abstract today:

http://sens.org/rb2014/posters

Steve Aoki joins SRF's Celebrity Reimagine Aging Campaign 

 

Grammy-nominated producer and musician Steve Aoki is the latest to speak his mind for our Celebrity Reimagine Aging campaign. Visit this special section of our Outreach site for our growing collection of exclusive perspectives on the topic of aging from a variety of authors, artists, inventors, enterpreneurs, and others. 

 

 

For more of Steve's take on life and the Neon Future he envisions, check out his recent Quora Q&A session via Forbes magazine -- and watch his Youtube channel for an uncoming feature interview with SRF CSO Dr. Aubrey de Grey!

 

Dr. Aubrey de Grey featured on 'Talks at Google'
 
SENS Research Foundation CSO Dr. Aubrey de Grey was recently featured in an episode of 'Talks at Google'. From the official YouTube channel,
 
"The Talks at Google program brings authors, musicians, innovators, and speakers of all stripes to Google for talks centering on their recently published books and capturing the popular and intellectual zeitgeist of the day."
 
 
Click the screenshot to see Aubrey's Ending Aging presentation.

 

Upcoming Events

 

May 17, 2014: 

TEDxOxbridge, Cambridge, UK. Dr. de Grey to speak.

 

June 10, 2014: 

Niagara Institutional Dialogue, Ontario, Canada. Dr. de Grey to speak

 
Visiting Santa Clara, CA for RB2014? Bring the Family Along!

 

Santa Clara, California is located in the heart of Silicon Valley, home to Google, Apple, Intel, HP, Facebook, and eBay. If you are planning on attending RB2014, consider bringing the whole family to enjoy the beautiful sunny weather and numerous local points of interest. Be sure to book your hotel room now to receive our special conference rate.

 

The Hyatt Regency Santa Clara hotel is directly across the street from the California Great America Theme park - a combination Amusement Park and Water Park. Great opportunity for attendees and their families to enjoy hours of fun.

 

For the technologically inclined, the Intel Museum (less than two miles from the hotel) offers a glimpse of silicon innovation from the inside. Head just a few miles over to Mountain View and you can tour the Computer History Museum.

 
Sports fans can check out the new Levi's Stadium, home of the San Francisco 49ers. The massive stadium is right next door to our conference venue and on August 24th the 49ers will play the San Diego Chargers.  
 
 
View of light rail station and Levi's stadium, Santa Clara
 
For those in the mood to explore, Santa Clara's central location offers trains to San Francisco and San Jose. The local transit system provides convenient options for getting around, and you can hop on the light rail right across from the hotel. 

 

Question Of The Month #3: Making SENS Part Of Medicine 

 

Q: I understand that aging specifically isn't an accepted target for therapy for regulatory purposes at present. How, then, will you get non-experimental therapies utilizing regenerative medicine techniques for the specific pathology of aging available to the common consumer?

 

A: That isn't nearly as big a challenge as is often portrayed. Remember, the damage-repair approach of SENS isn't an all-in-one treatment with the indication "aging," but a divide-and-conquer strategy to develop a suite of rejuvenation biotechnologies that each remove, repair, replace, or render harmless one of many specific form of cellular and molecular damage that accumulate in aging bodies. Thus, no one rejuvenation biotechnology will arrest or reverse the degenerative aging process or prevent all of its diseases and disabilities. Ironically, then, even if regulators were to develop an indication for "aging," individual rejuvenation biotechnologies wouldn't qualify!
 
By contrast, most forms of aging damage can be quite clearly linked with specific diseases of aging: beta-amyloid protein and malformed tau species for Alzheimer's; lysosomal aggregates in the arterial macrophage/foam cell with atherosclerosis (and through it heart attacks and stroke); cross-linked proteins with hypertension (and through it congestive heart failure, renal disease, and stroke); alpha-synuclein and Parkinson's disease; and so on.
 
In other cases, rejuvenation biotechnologies could initially be licensed as treatments for certain genetic disorders, even though the /cause/ of the pathology underlying those diseases may not be related to the universal degenerative aging process. This is true, for instance, for most mitochondriopathies (inherited disorders of the mitochondria, many of which are caused by mutations in individual protein-encoding mitochondrial genes). Even though the mutations in these patients are inherited rather than acquired as a result of later metabolic mishaps, the same damage-repair approach (allotopic expression of the protein from the nucleus) can be used to replace the missing or defective protein in the mitochondrial energy-production chain and restore normal cellular function.
 
So the great majority of rejuvenation biotechnologies -- and probably all of them -- can be developed as therapies for diseases that are either already accepted as licensable indications, or in a few cases are very likely to be accepted soon (notably, sarcopenia (the loss of muscle mass and quality with aging)). Whether degenerative aging is "a disease" or not, and whether it is recognized as such by regulators, is of no consequence to the practical business of turning rejuvenation biotechnology into therapies against its associated conditions.
-Michael

The "Question of the Month" column is your opportunity to submit your research-related queries to SRF's expert science writer Michael Rae. Please send your questions to foundation@sens.org and they may be featured in a future newsletter.

 

 

 

Want to help spread the word about SRF's mission?

 

Share our vision to Reimagine Aging on

 

   Facebook       @SENSTweet

 


Want to support SRF's work? Donate today!

 

As a 501(c)(3) public charity, SENS Research Foundation relies on your support

to continue our mission to change the way the world researches and treats age-related disease.

 

 

Visit our donate page to make your contribution.